范跃祖 主任医师，教授
硕士招生类型：学术型、专业型
硕士招生专业：外科学（普外科）
博士招生类型：学术型、专业型
博士招生专业：外科学（普外科）
所在院系：附属同济医院
联系方式：fanyuezu@tongji.edu.cn
课题组链接：
研究方向
主要任职
科研业绩

胆胰外科疾病和消化系肿瘤的外科综合治疗及其相关基础研究


同济大学外科学教授、主任医师、博士生导师；同济大学附属同济医院大外科、外科教研室主任；国际胃肠外科俱乐部、欧洲消化外科学会会员，中国医师协会外科医师分会、上海市医学会外科学会、普外科专业分会、普外科胆道外科和胰腺外科专业组委员，上海市中西医结合外科学会常委，国家自然科学基金委员会（生命科学部-肿瘤/普外）、国家及上海市继续医学教育项目评审专家，上海市医疗事故技术鉴定专家，《World Journal Gastrointestinal Surgery》、《Molecular and Clinical Oncology》杂志编委，《中国医学文摘外科学(英文版)》、《外科研究与新技术（中英文杂志）》副主编。


主要科研项目：
1. 国家自然科学基金面上项目：高侵袭性胆囊癌“抗血管生成拟态治疗”及相关分子机制研究.（30万，编号**），2007.01-2009.12；项目负责人：范跃祖；
2. 国家自然科学基金面上项目：纳米去甲斑蝥素联合mF4-31C1/sorafenib靶向抗VEGF- C/-D介导的结肠腺癌淋巴管生成及其相关机制研究. （28万，编号**）2011.01- 2013.12；项目负责人：范跃祖；
3. 国家自然科学基金面上项目：胆囊癌相关成纤维细胞促进胆囊癌血管新生及其分子机制和干预研究.（70万，编号**），2014.01-2017.12；项目负责人：范跃祖；
4. 教育部博士研究生学术新人奖项目（2011年度）：肿瘤相关成纤维细胞（CAFs）对胆囊癌相关基因表达的影响、干预机制及临床预后研究. （3万，编号）. 2012.01- 2014.12孙伟博士/范跃祖导师；
5. 上海市科委纳米专项课题：基于磁热效应的纳米药物传输系统的制备技术及其在肿瘤热化疗治疗中的应用研究（60万，编号11nm**）,2012.01-2014.12；项目负责人：任杰（药物制备），范跃祖（细胞动物实验-安全性和抗肿瘤疗效研究）；
6. 上海市自然科学基金项目：胆囊癌相关成纤维细胞促血管生成拟态基因谱表达筛选研究（10万，编号13ZR**），2014-01-01~2016-12-31； 项目负责人/导师：孙伟/范跃祖

主要论文（第1或通讯作者）：
1. Fan YZ, Zhao ZM, Fu JY, Chen CQ, Sun W. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat Dis Int 2010; 9(4): 414-422
2. Ge BJ, Huang Q, Liu LM, Bian HP, Fan YZ. Risk factors for bowel resection and outcome in patients with incarcerated groin hernias. Hernia 2010; 14(3): 259–264.
3. Fan YZ, Sun W. Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy.World J Gastrointestinal Surgery 2010; 2(4):117-127
4. Li XP, Liu WF, Ji SR, Wu SH, Sun JJ, Fan YZ. Isolated pancreatic granulocytic sarcoma: A case report and review of the literature. World J Gastroenterol 2011; 17(4): 540-542
5. Sun W, Fan YZ, Zhang WZ, Ge CY. A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res 2011, 30:46-58
6. Sun W, Fan YZ, Xi H. Astrocyte elevated gene-1 (AEG-1) overexpression in human primary gallbladder carcinomas: an unfavorable and independent prognostic factor. Oncol Rep 2011; 26(5):1133-1142
7. Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W. Norcantharidin: A potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol 2012, 40(5):1501-1514
8. Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W. Norcantharidin: A potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol 2012, 40(5):1501-1514
9. Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ, Zhang JT, Lu XS, Ye C. Overexpression of HIF-1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavorable prognosis. Oncol Reports 2012, 27(6):1990-2002
10. Sun JJ, Jing W, Ni YY, Yuan XJ, Zhou HH, Fan YZ. New model of in-situ xenograft lymphangiogenesis by a human colonic adenocarcinoma cell line in nude mice. Asian Pacific J Cancer Prev 2012, 13(6):2823-2828
11. Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W, Fan YZ. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and -D/VEGFR-3 with norcantharidin. Int J Oncol2012, 41(5):1762-1772
12. Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W. Norcantharidin: A potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Mol Med 2012, 30(Suppl 1):S39
13. Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W, Fan YZ. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and -D/VEGFR-3 with norcantharidin. Int J Mol Med 2012, 30(Suppl 1):S40
14. Lu XS, Sun W, Ge CY, Zhang WZ, Fan YZ. Contribution of the PI3-K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol 2013, 42(6):2103-2115
15. Zhang JT, Sun W, Zhang WZ, Ge CY, Liu ZY, Zhao ZM, Lu XS, Fan YZ. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ² signaling pathway. BMC Cancer 2014, 14:193.
16. Wang H, Sun W, Zhang WZ, Ge CY, Zhang JT, Liu ZY, Fan YZ. Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/Paxillin signaling pathway. PLoS One 2014, 9(5): e96882.
17. Zhu W, Sun W, Zhang JT, Liu ZY, Li XP, Fan YZ. Norcantharidin enhances TIMP-2 anti-vasculogenic mimicry activity for human gallbladder cancers through downregulating MMP-2 and MT1-MMP. Int J Oncol 2015, 46:627-640
18. Yuan XJ, Chen Y, Li XM, Zhang GN, Jin DH, Zhao HF, Su ZW, Fan YZ. Norcantharidin inhibits lymphangiogenesis by downregulating the expression of VEGF-C and VEGF-D in human dermal lymphatic endothelial cells in vitro. Pharmacology 2015(1-), 95:1-9
19. Li XP, Jin W, Sun JJ, Liu ZY, Zhang JT, Sun W, Zhu W, Fan YZ. Norcantharidin, a potential small-molecule synthetic antilymphangiogenic agent, inhibits colonic adenocarcinoma lymphangiogenesis through arresting S-phasecell cycle and VEGF-A, -C, -D/VEGFR-2, -3 signaling pathways in vitro and in vivo. Eur Surg 2015, 47(Suppl 1): S75-S76
20. Li XP, Jin W, Sun JJ, Liu ZY, Zhang JT, Sun W, Zhu W, Fan YZ. A potential small-molecule syntheticantilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A, -C, -D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro andin vivo. BMC Cancer 2015, 15:527